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Understanding the rationale of the well-stirred model (WSM), borrowed from chemical engineering, has been
ongoing through the history of pharmacokinetics (PK) as an independent discipline. Extensive arguments around
the WSM and 1977′ s lidocaine data re-emerged recently. It was proposed that Pang and Rowland’s lidocaine data
analysis was confounded by four intermingled confounding factors which may lead to contradictory conclusions
or inconclusive dilemma. This re-visit of 1977′ s lidocaine data analysis was challenged by Pang and coauthors.
This commentary is our responses to their comments focusing on the lidocaine data analysis and the IVIVE by the
WSM. In addition, the disadvantage of applying the well-stirred model in drug-drug interaction (DDI) prediction
and a theoretical dilemma in the commonly used whole-body physiologically based pharmacokinetic (PBPK)
models were discussed.

1. Introduction
It has been well recognized that the well-stirred model (WSM) gives
poor in vitro-in vivo extrapolation (IVIVE) for high clearance drugs (Chiba
et al., 2009; Watanabe et al., 2009) (note: drugs with hepatic extraction
ratios (Eh,B ) greater than 0.8 are considered as high clearance drugs
while the ones with Eh,B less than 0.8 are low-to-moderate clearance
drugs in this paper). However, 1977′ s lidocaine data suggested that the
WSM is better than the parallel-tube model (PTM) when the lidocaine
Eh,B was higher than 0.99 (Pang and Rowland, 1977). A re-analysis was
performed to clarify the discrepancy (Dong and Park, 2018). The results
showed: (a) the WSM is very similar to the PTM and dispersion model
(DM) when predicting Eh,B or clearance for low-to-moderate and high
clearance drugs, (b) the PTM is better than the WSM when estimating
intrinsic clearance (CLh,int ) for high clearance drugs, (c) neither WSM nor
PTM is recommended to predict hepatic availability (Fh,B ) for high
clearance drugs (Dong and Park, 2018). Recently, Pang and coauthors
(Pang et al., 2019) challenged the re-analysis. Herein, we would like to
respond to Pang and coauthor’s arguments focusing on the lidocaine
data analysis and the IVIVE by the WSM. In addition, the disadvantage of
applying the well-stirred model in drug-drug interaction (DDI) predic
tion and a theoretical dilemma in the commonly used whole-body
physiologically based pharmacokinetic (PBPK) models were discussed.
2. Four intermingled factors
The concerns on 1977′ s lidocaine data analysis was not due to a
single factor of sensitivity or relative error but four intermingled factors
(Dong and Park, 2018). The four intermingled factors may cause un
stable comparison and depending on the selection of the control

condition, could lead to different conclusions and sometimes inconclu
sive result dilemma, such as for diazepam and diclofenac as shown in the
previous paper (Dong and Park, 2018). In addition, regardless of the
relationship between the WSM and PTM, the simulation by the DM is
expected to be closer to the observed values than the WSM, given that
the WSM is an approximation or extreme case of the DM. Yet, the
conclusion drawn using 1977′ s lidocaine data is the opposite, as shown
in Fig. 1A. The four intermingled factors incorporating the comparison
with the simulations by the DM were further discussed in the Appendix
A in the Supplementary Materials following the same strategy we re
ported previously (Dong and Park, 2018). Fig. 1A is a result of: on the
WSM side, it has high relative error for estimating CLh,int and predicting
Fh,B ; on the PTM and DM side, they have too high sensitivity for pre
dicting Fh,B . And the instability issue was amplified by using different
back-calculated CLh,int values for simulation. All the four factors inter
mingled together leading to an unstable and less reliable comparison of
the WSM and the PTM/DM.
3. Comparison by IVIVE of lidocaine
Pang and coauthors challenged the comparison approach of using
the same in vitro CLh, int to predict in vivo Eh,B with the WSM and PTM. In
fact, this is one of the most common practices of IVIVE in both academia
and industry.
Today’s IVIVE is not perfect yet but it does not mean it always causes
misprediction, especially underprediction. The commonly observed
underprediction occurs more often for drugs as substrates of trans
porters, non-cytochrome P450 (non-CYP) enzymes, or having high
plasma protein binding (Bowman and Benet, 2016, 2019; Poulin et al.,
2012). It is critical to apply the knowledge of elimination routes and the

Abbreviations: AUC, area under the curve; BDDCS, biopharmaceutical drug disposition classification system; CYP, cytochrome P450; DDI, drug-drug interaction;
DM, dispersion model; ECCS, extended clearance classification system; IVIVE, in vitro-in vivo extrapolation; non-CYP, non-cytochrome P450; PBPK, physiologically
based pharmacokinetics; PK, pharmacokinetics; PTM, parallel-tube model; WSM, well-stirred model.
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Fig. 1. (A). The observed and simulated output lidocaine concentrations (Ch,B,out ) at different flow rates divided by observed output lidocaine concentrations at the
control flow rate of 10 mL/min (Ch,B,out,cont ) (Pang and Rowland, 1977). (B). Drugs with baseline Eh,B from 0.1 to 0.999 upon 1 to 50-fold reduction in their CLh,int . It
was assumed that: i) overall bioavailability is 1 (intravenous administration); ii) hepatic elimination is the only elimination route; iii) fu,B and Qh,B are not changed.
Eh,B,WSM is calculated by the WSM with the reduced CLh,int (baseline CLh,int /fold reduction. Baseline CLh,int was estimated by the WSM from the baseline Eh,B ).
Similarly, Eh,B,DM0.3 is calculated by the DM (DN = 0.3) with the reduced CLh,int (baseline CLh,int /fold reduction. Baseline CLh,int was calculated by the DM from the
K

app,T:P
same baseline Eh,B ). (C) The fold difference of KNE,app,T:P to KNE,app,O:P (calculated by Kapp,O:P
) when KNE,app,T:P is in the range of 0.01~200 and RB:P is assumed as 1. Heart,

fraction of vascular space of 0.16, blue; liver, fraction of vascular space of 0.27, gray; kidney, fraction of vascular space of 0.36, orange; lung, fraction of vascular
space of 0.53, yellow. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

involvement of transporters and non-CYP enzymes before the effort of
evaluating the IVIVE using traditional metabolism-based in vitro assays
such as microsome and suspended hepatocyte assays. In contrast, one
may have higher confidence on establishing metabolism prediction for
drugs metabolized by CYP enzymes with high passive permeability and
low to moderate plasma protein binding. Otherwise, the evaluation of
the goodness of IVIVE may be confounded. In the case of lidocaine, it is a
biopharmaceutical drug disposition classification system (BDDCS) class
I or extended clearance classification system (ECCS) class II drug with
high passive permeability. It is primarily metabolized by CYP enzymes.
Its unbound fraction in the perfusate (fu,pf ) in 1977′ s lidocaine study was
0.95 (Pang and Rowland, 1977). And, its plasma protein binding in rat,
monkey, and human are 0.43, 0.39, and 0.33, respectively (Lombardo
et al., 2013). Thus, lidocaine is one of the drugs one may have higher
confidence on its IVIVE.
In addition, if the in vitro and in vivo CLh,int showed good correlation
by the PTM and DM model while there is significant underprediction by
the WSM for a high clearance drug, such as observed in lidocaine, an
IVIVE may be established and the mismatch by the WSM could be due to
the overestimation issue of the WSM itself which has been well discussed
(Chiba et al., 2009; Dong and Park, 2018).

commonly used PBPK models in their mass balance when the vascular
spaces of each organs are lumped to the arterial and venous blood
reservoirs.
Herein we briefly discuss the well-stirred non-eliminating organ
model only (the detailed theoretical derivations including the liver
model are presented in Appendix C). The following equation is used in
the traditional PBPK models (Jones and Rowland-Yeo, 2013; Peters,
2012).
VNE,T ⋅

)
(
dCNE,T
= QNE,B ⋅ CNE,B,in − CNE,B,out
dt

(1)

where CNE,B,in and CNE,B,out are the blood concentration of drug entering
and leaving the non-eliminating organ, respectively; CNE,T is the tissue
concentration of the non-eliminating organ; VNE,T is the tissue volume
(which excludes the vascular space) of the non-eliminating organ; QNE,B
is the blood flow rate of the non-eliminating organ.
To relate CNE,B,out and CNE,T and reduce the number of unknown
variables, Eq. (2) was proposed under the assumption of perfusion
limited transport (Jones and Rowland-Yeo, 2013; Jones et al., 2006;
Peters, 2012)
CNE,B,out =

4. The well-stirred model for DDI

CNE,T
CNE,T
/
=
KNE,app,T:P RB:P KNE,app,T:B

(2)

where KNE,app,T:P and KNE,app,T:B are the apparent partition coefficient of
drug between the tissue and the emergent venous plasma and blood of
the non-eliminating organ, respectively; RB:P is the blood to plasma
ratio. Here, the tissue concentration in the definition of KNE,app,T:P is “a
concentration of drug in a tissue outside of the blood perfusing it”
(Rodgers et al., 2005). In other words, the blood concentration is
excluded in the calculation of the tissue concentration.
However, the total change rate in the amount of drug in the noneliminating organ should include both vascular and tissue spaces as

The WSM has distinct mathematical features of the relative error and
sensitivity when estimating in vivo CLh,int for low-to-moderate and high
clearance drugs (Dong and Park, 2018), while it is common to use
back-calculated in vivo CLh,int from in vivo clearance by the WSM.
However, it was shown in Fig. 1B that the back-calculated in vivo CLh,int
from in vivo clearance using the WSM may lead to underprediction
(<0.8) of area under the curve (AUC) for drugs with baseline Eh,B greater
than 0.5 upon larger than 3.3-fold reduction in their CLh,int compared
with using the DM (DN = 0.3). Drugs with very high baseline Eh,B may be
immune from the < 0.8-fold of difference due to CLh,int reduction. For
example, the fold difference was 0.91 for drugs with baseline Eh,B of
0.999 upon 5-fold reduction in CLh,int . This is because the reduced CLh,int
is still very high making the drugs as high extraction ratio drugs whose
clearance is dominated by the blood flow rate. In addition, it is not a
problem when predicting the AUC reductions due to CLh,int induction
using in vivo CLh,int back-calculated with the WSM, as shown in Fig. S1.
Albeit the limitation of the above analysis performed under the
assumption of steady state, the preliminary simulation results suggested
that the use of WSM for back-calculating CLh,int in physiologically based
pharmacokinetic (PBPK) modeling warrants further investigation on its
potential impact on the simulation in the scenarios when the drug Eh,B
varies over a large range across the category of low-to-medium and high
clearance, especially due to CLh,int reduction (e.g., drug-drug interaction
(DDI), polymorphism, disease effect, pediatrics, etc.).

)
(
dANE dANE,B dANE,T
dCNE
=
+
= VNE ⋅
= QNE,B ⋅ CNE,B,in − CNE,B,out
dt
dt
dt
dt

(3)

where ANE , ANE,B , and ANE,T are the total drug amount (includes both
vascular and tissue spaces), the drug amount in the vascular space and
the drug amount in the tissue space in the whole non-eliminating organ,
respectively; CNE and VNE are the average organ concentration and total
volume of the non-eliminating organ.
Comparing Eq. (1) with Eq. (3), the right-hand side of these two
equations are exactly the same while the left-hand sides are different. In
dC

the traditional non-eliminating organ model, VNE,T ⋅ dtNE,T is not the total
change rate in the amount of drug in the whole non-eliminating organ,
which includes both vascular and tissue spaces. Eq. (1) does not hold the
principle of mass conservation except when all the change rates are zero
under steady state. If the traditional definition of CNE,T is a misphrasing
but in practice the average concentration of the whole organ in the
traditional PBPK modeling is used, then the use of Eq. (2) is inappro
priate, especially when KNE,app,T:B is not 1 (the average drug concentra
tion of the whole non-eliminating organ CNE is not equal to CNE,T ). This is
because the blood concentration is not being taken into account for
calculating the average concentration of the whole organ. KNE,app,O:P , the

5. The theoretical dilemma in PBPK models relating to
concentration calculation
Population based PBPK is critical to incorporate the variabilities in
clearance prediction. However, a theoretical dilemma is found from the
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ratio between CNE and CNE,B,out , rather than KNE,app,T:P , is needed for
solving Eq. (3).
KNE,app,O:P = KNE,app,T:P ⋅

VNE,T
VNE,B
+ RB:P ⋅
VNE,B + VNE,T
VNE,B + VNE,T
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(4)

where VNE,B is the blood volume of the non-eliminating organ.
Eq. (4) and Fig. S4 suggested that the difference between KNE,app,O:P
and KNE,app,T:P is larger in richly perfused organs such as heart, liver,
kidney and lung with fraction of vascular space of 0.16, 0.23~0.36,
0.14~0.27, 0.53, respectively (Table S1). The simulation results showed
larger than two-fold difference in drugs with heart, kidney, liver, and
lung Kapp,T:P less than 0.138, 0.265, 0.213, and 0.346 assuming RB:P as 1
(Fig. 1C). For example, ceftazidime showed KNE,app,T:P /KNE,app,O:P of 0.09
for heart, 0.12 for liver, and 0.13 for lung in the rat (Table S2; KNE,app,T:P
/KNE,app,O:P of 0.88 for kidney due to the relatively high observed
KNE,app,T:P of 0.54 greater than 0.265; KNE,app,T:P /KNE,app,O:P of 0.15 for
heart, 0.20 for liver, and 0.21 for lung assuming RB:P as 0.55).
As the vascular space should be taken into account in each organ
model to maintain its mass balance, the blood reservoir compartments
are removed to avoid doubling the vascular space in the whole-body
PBPK model. The lung compartment becomes
Vlung ⋅

dClung ∑
=
Qi,B ⋅ Ci,B,out − Qlung,B ⋅ Clung,B,out
dt

Supplementary materials
Supplementary material associated with this article can be found, in
the online version, at doi:10.1016/j.ejps.2022.106134.
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(5)

where Clung , Vlung , and Qlung,B are the average organ concentration, the
total volume, and the blood flow rate of the lung (which is equal to the
cardiac output), respectively; Ci,B,out and Qi,B are the blood concentration
of drug leaving the ith organ and the blood flow rate of the ith organ,
respectively. Therefore, it is critical to incorporate the “peripheral
sampling site” model (Musther et al., 2015) to simulate the sampled
blood/plasma concentration.
6. Conclusions
Regardless of the relationship between the WSM and PTM, the WSM
is an extreme case of the DM according to Roberts and Rowland’s theory.
However, why does lidocaine data show the WSM to be better than the
DM? How to explain the contradictory or inconclusive comparison of the
WSM and PTM using diazepam and diclofenac data by applying 1977′ s
lidocaine data analysis method? These were not addressed in the com
mentary (Pang et al., 2019).
In contrast, the IVIVE approach showed the PTM and DM were better
than the WSM for lidocaine, diazepam, and diclofenac by avoiding the
relative error issues of the WSM and stability issues of the PTM and DM
when predicting Fh,B (Dong and Park, 2018). Caution may be needed
when using the WSM for building IVIVE for high clearance drugs when
predicting Fh,B and estimating CLh,int and when using WSM to
back-calculate CLh,int for drugs with Eh,B higher than 0.5 for scenarios
such as simulating inhibition-mediated DDI. In addition, the theoretical
dilemma in mass balance of the PBPK models warrants further
investigation.
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